Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6173777 | European Journal of Obstetrics & Gynecology and Reproductive Biology | 2014 | 6 Pages |
Abstract
In the malignant group, 23 of 41 patients (56.1%) had high ERK1/2 and p-AKT expression, whereas only three of 48 patients in the benign group (6.3%) had high ERK1/2 and p-AKT expression (PÂ <Â 0.0001 and PÂ <Â 0.0001, respectively). p-AKT expression was significantly higher in women with positive lymph nodes (OR 9.0; 95% CI: 1.2-100.0; PÂ =Â 0.03). Higher expression of p-AKT was significantly associated with poor progression-free survival (PFS) and overall survival (OS). In contrast, ERK1/2 expression was not associated with PFS or OS.Conclusions ERK1/2 and p-AKT can be useful in the differential diagnosis of benign vs. malignant endometrial lesions, as well as early vs. advanced stage endometrioid endometrial adenocancer. Additionally, higher p-AKT expression could be used as a marker of poor prognosis in the management of patients with endometrioid endometrial adenocancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Kemal Gungorduk, Ibrahim Egemen Ertas, Ahmet Sahbaz, Seyfettin Ozvural, Yagmur Sarica, Aykut Ozdemir, Sevil Sayhan, Mehmet Gokcu, Bulent Yilmaz, Muzaffer Sanci, Sevinc Inan, Mehmet Harma, Yusuf Yildirim,